| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Revenue | 348 | 19,145 | 2,978 | 29,111 |
| Research and development expenses | 30,971 | 27,516 | 44,751 | 35,702 |
| Selling, general and administrative expenses | 24,520 | 27,264 | 27,152 | 18,412 |
| Total operating expenses | 55,491 | 54,780 | 71,903 | 54,114 |
| Operating loss | -55,143 | -35,635 | -68,925 | -25,003 |
| Interest income | 6,713 | 7,055 | 7,351 | 4,443 |
| Fair value change - warrants | 23,792 | -2,590 | -13,762 | - |
| Change in fair value of earnout and warrants | - | - | - | 770 |
| Loss on disposal of property, plant and equipment | -1 | - | - | - |
| Fair value change - earnout | - | - | -3,992 | - |
| Foreign exchange gains/(losses) | 218 | 8,626 | 4,293 | 4,682 |
| Loss before tax | -72,005 | -17,364 | -39,527 | -16,648 |
| Loss for the period | -72,005 | -17,364 | -39,527 | - |
| Income tax expense (benefit) | - | - | - | -1 |
| Unrealized gain/(loss) on available-for-sale securities, net of tax | 313 | -107 | -33 | - |
| Total comprehensive loss for the period, net of tax | -71,692 | -17,471 | -39,560 | -16,647 |
| Earnings per share, basic | -0.61 | -0.15 | -0.34 | -0.18 |
| Earnings per share, diluted | -0.61 | -0.15 | -0.34 | -0.18 |
| Weighted average number of shares outstanding, basic | 119,000,266 | 118,556,492 | 116,124,941 | 94,754,140 |
| Weighted average number of shares outstanding, diluted | 119,000,266 | 118,556,492 | 116,124,941 | 94,754,140 |
NewAmsterdam Pharma Co N.V. (NAMS)
NewAmsterdam Pharma Co N.V. (NAMS)